Asensus Surgical — TransEnterix — Investor Presentation (June 2015)
23 slides from Asensus Surgical's investor presentation, Jun 8, 2015
Slide 1: Todd M. Pope, President & CEO; Joe Slattery, EVP & CFO
Todd M. Pope, President & CEO Joe Slattery, EVP & CFO June 8, 2015 Exhibit 99.1
Slide 2: Cautionary Statement
Cautionary Statement 2 TransEnterix, Inc. (“TransEnterix,” “we” or “our”) has filed a registration statement (including a prospectus) and a preliminary prospectus supplement with the Securities and Exchange Commission (“SEC”) for the offering to which this presentation relates. Before you invest you
Slide 3: Advancing Surgery Through Innovation
Advancing Surgery Through Innovation
Slide 4: Transaction Overview
Transaction Overview Issuer: TransEnterix, Inc. Ticker (Exchange): TRXC (NYSE MKT) Amount Offered: $50 million common stock Option to Purchase Additional Shares: 15% Lock-up Provision: 90 days Expected Pricing: XXXXX Bookrunners: Stifel / RBC Capital Markets Use of Proceeds: For research and develop
Slide 5: Investment Highlights
Investment Highlights Focus Technology Solution Market Experience The SurgiBot System is currently in development • Surgical robotics • Developing patient-side robotic platform, SurgiBot System • Addresses unmet needs in today’s robotic offerings • Cost effective • Broad procedure applicability • La
Slide 6: Surgical Progress = Less Invasive
Surgical Progress = Less Invasive 6 Open Surgery Rigid Laparoscopy (1989) Flexible Laparoscopy (2010)
Slide 7: Spider Surgical System Enabling Flexible Laparoscopy
Spider Surgical System Enabling Flexible Laparoscopy 7 • Internal (intra-abdominal) triangulation • Flexible, articulating instruments for dissection and retraction • True left/right instrumentation • Lower profile port of access • Over 3,500 procedures performed • Broad procedural mix
Slide 8: Robotically-enabled Laparoscopic Platform
Robotically-enabled Laparoscopic Platform The SurgiBot System is currently in development
Slide 9: Benefits of Surgical Robotics
Benefits of Surgical Robotics 9 Benefits of Surgical Robotics Improved dissection and retraction strength Enhanced precision and control Improved surgeon ergonomics Advanced visualization
Slide 10: SurgiBot Patient-side Robotic Platform
SurgiBot Patient-side Robotic Platform 3DHD Vision Cart SurgiBot The SurgiBot System is currently in development
Slide 11: SurgiBot Patient-side Robotic Platform (Video)
SurgiBot Patient - side Robotic Platform [Video of SurgiBot™ System] The SurgiBot System is currently in development
Slide 12: SurgiBot Features
SurgiBot Surgeon scrubbed-in Easily repositioned for multi- quadrant surgery Flexible, articulating channels & instruments Steerable 3DHD Vision Small, mobile platform Cost effective platform Patient-side Robotic Platform The SurgiBot System is currently in development
Slide 13: Procedure Market Opportunity
Procedure Market Opportunity 13 Bariatric Surgery Cholecystectomy Colorectal Gynecology/Urology Targeted US Procedures 160K 1,140K 363K 230K Source: Millennium Research Group US Markets Laparoscopic Devices 2014 ~2M US Laparoscopic Procedures
Slide 14: Hospital Market Opportunity
Hospital Market Opportunity 14 Hospitals without Robotic Capability Hospitals with Robotic Capability • Current robotic offerings are not cost effective • System price • Limited procedure volume • Surgery centers – untapped market for robotics • Losing market share to robotic facilities • Large unde
Slide 15: Significant Base of Underserved Hospitals
Significant Base of Underserved Hospitals 15 Mid/Small Hospitals Surgery Centers • >3,000 w/ <300 beds • >80% lack robotic offering • Losing market share to robotic facilities • Represent >800K target annual procedures • ~5,000 in US • Economics driving rapid procedure growth • SurgiBot will offer v
Slide 16: Combining Advanced Technology and Maximizing Value
Combining Advanced Technology AND Maximizing Value 16 Price Surgical Robotics >$2B Revenue High Growth Traditional Laparoscopy >$10B Revenue Low Growth
Slide 17: Recurring Revenue Model
Recurring Revenue Model 17 Instruments and Accessories Service Capital Equipment • US Pricing: • Capital sale ~$500K • Instruments ~$1,000-1,500/procedure • Service ~$50K/year • International: • Market-specific pricing • Distributors provide service/support The SurgiBot System is currently in develo
Slide 18: Highlights – Instrumentation
Highlights – Instrumentation 18 Instrumentation Needs By Procedure Status Chole Bariatrics GYN SPIDER SurgiBot Launched Developed Launched Developed Launched Developed Launched Developed Launched Developed Launched Developed Launched Developed Launched Development 3 rd Party Development 3 rd Party 3
Slide 19: Advanced Energy
Advanced Energy [Video of Flex Ligating Shears as Compared to Competition] Superior Visualization – Degree Articulation
Slide 20: Milestones
Milestones 20 • 510(k) submitted June 2015 • Anticipate 6-9 month review cycle • Anticipate commercial launch Q2 2016 The SurgiBot System is currently in development
Slide 21: Operating Capabilities & Talent
Operating Capabilities & Talent 21 Rapid Prototyping R&D Team Broad Experience cGMP Manufacturing
Slide 22: Management Team
Management Team 22 Prior Experience Todd M. Pope President and Chief Executive Officer Joe Slattery EVP and Chief Financial Officer Mohan Nathan Vice President of Global Marketing Vernon Brown Vice President, Quality and Regulatory Affairs Nicole Bell Vice President, Research and Development Larry P
Slide 23: TransEnterix – advancing surgery through innovation
= onsEneerie advancing surgery through innovation® ransEnterix